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Abstract
Background: Recent studies suggested that bone marrow (BM) cell implantation in patients with severe chronic
coronary artery disease (CAD) resulted in modest improvement in symptoms and cardiac function. This study
sought to investigate the functional changes that occur within the chronic human ischaemic myocardium after
direct endomyocardial BM cells implantation by cardiovascular magnetic resonance (CMR).
Methods and Results: We compared the interval changes of left ventricular ejection fraction (LVEF), myocardial
perfusion reserve and the extent of myocardial scar by using late gadolinium enhancement CMR in 12 patients
with severe CAD. CMR was performed at baseline and at 6 months after catheter-based direct endomyocardial
autologous BM cell (n = 12) injection to viable ischaemic myocardium as guided by electromechanical mapping. In
patients randomized to receive BM cell injection, there was significant decrease in percentage area of peri-infarct
regions (-23.6%, P = 0.04) and increase in global LVEF (+9.0%, P = 0.02), the percentage of regional wall thickening
(+13.1%, P= 0.04) and MPR (+0.25%, P = 0.03) over the target area at 6-months compared with baseline.
Conclusions: Direct endomyocardial implantation of autologous BM cells significantly improved global LVEF,
regional wall thickening and myocardial perfusion reserve, and reduced percentage area of peri-infarct regions in
patients with severe CAD.
Background
Recent clinical studies [1-5] suggest that direct implan-
tation of autologous bone marrow (BM) cells into the
ischaemic myocardium improves symptoms and exercise
capacity and increases left ventricular (LV) function in
patients with severe coronary artery disease (CAD).
Despite the absence of trans-differentiation of trans-
planted BM cells into ischaemic myocardium, improve-
ment in LV function is observed in experimental studies
[6,7]. Indeed, emerging evidences from experimental
studies indicate than BM cells might exert their benefit
via paracrine effects to induce angiogenesis in
myocardial ischaemia [6,8,9]. However, there is very lim-
ited data on the functional effects of direct BM cells
implantation in human [1,2]. Advances in cardiovascular
magnetic resonance (CMR) allow non-invasive assess-
ment and serial monitoring of myocardial perfusion by
capturing the first-pass perfusion of a bolus of gadoli-
nium injection [10-13]. Furthermore, the use of late
gadolinium enhancement (LGE) CMR can identify and
quantity the amount of heterogeneous zone of viable
and nonviable peri-infarct myocardium, which has been
shown to be a powerful predictor for mortality in post
myocardial infarction patients [14]. In this study, we
sought to investigate the changes in myocardial func-
tion, perfusion and myocardial scar using CMR imaging
in patients with severe CAD following direct endomyo-
cardial BM cells implantation.
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Study Population
Among those 28 patients enrolled into a Phase I-II ran-
domized PROTECT-CAD trial to evaluate the safety
and feasibility of using a catheter-based intramyocardial
autologous BM cells implantation [15], we performed a
subgroup analysis in 12 patients recruited in Hong Kong
who had received BM cells injection in whom detailed
CMR was performed using the same imaging protocol.
The details of inclusion, exclusion criteria and study
protocol have been reported previously [15]. As reported
previously [15], patients treated with BM cell injection
had significant improvement in global and regional LV
function as measured by CMR compared with controls.
This is a post-hoc exploratory analysis to study the
changes in CMR parameters in patients treated with BM
injections which were not included in the predefined
analysis of the PROTECT-CAD trial.
Study Protocol
In brief, all patients enrolled into PROTECT-CAD trial
were suffered from severe CAD with reversible perfusion
defects detected by single-photon emission computed
tomography and had no other option for conventional
revascularization therapies. All patients gave informed
consent, and the protocol was approved by the institu-
tional review boards. The study population was rando-
mized to receive direct intramyocardial injection of
either BM cells (BM group) or autologous plasma (con-
trols) into chronic ischemic myocardium as guided by
electromechanical mapping in 2:1 ratio [15].
In this sub-study, all patients were randomized to the
BM group. As reported previously [1,15], mononuclear
cells at a concentration of 1 × 10
7 cells per ml were pre-
pared by Ficoll density gradient centrifugation of autolo-
gous BM cells harvested from the right iliac crest in
each patient. The cell viability was >95% and intramyo-
cardial injection was performed immediately after pre-
paration (~3 hours after harvesting). All patients
underwent non-fluoroscopic LV electromechanical map-
ping (NOGA system, Biosense-Webster) to identify tar-
geted ischaemic myocardium which was matched
SPECT and CMR perfusion imaging [1-5,15]. At each
targeted ischaemic region, injections of 0.1 ml of mono-
nuclear cell suspension were delivered as guided by elec-
tromechanical mapping [15].
CMR Protocol
Cine CMR
CMR was performed at baseline and at 6 months after
catheter-based direct endomyocardial autologous BM
cell, and within one week after the single-photon emis-
sion computed tomography examination. All patients
were examined in the supine position with a 1.5 T
system (CV/I, General Electric, Milwaukee, Wisconsin),
using a four-element phased-array cardiac coil. All
images were obtained during repeated breath-holds.
Cine images were performed in multiple parallel short-
axis planes covering the entire LV using an ECG-gated
segmented K space, steady state free precession pulse
sequence as previously reported [14-16].
Adenosine First Pass Perfusion CMR
An intravenous bolus of 0.05 mmol/kg gadolinium-
DTPA (Magnevist, Schering) was administered at a rate
of 5 ml/s by a power injector 4 minutes after continuous
adenosine infusion at 140 mg/kg/min. All patients were
under continuous blood pressure, pulse oximetry and
electrocardiogram monitoring. First-pass perfusion ima-
ging was performed simultaneously with contrast injec-
tion for the first 30 to 60 heart beats, using a saturation
recovery interleaved fast gradient echo-echo planar pulse
sequence at three short-axis left ventricular level (basal,
mid ventricular and apical) as previously reported
[14-16]. After a twenty minute waiting period for equili-
bration of the contrast agent within the myocardium, the
resting first pass perfusion imaging using the same ima-
ging parameters and same slice locations were acquired.
Late Gadolinium Enhancement (LGE) CMR
According to a previously described inversion recovery
pulse sequence (repetition time, 4.8 ms; echo time, 1.4
ms; in-plane spatial resolution between 1.5-1.8 mm and
1.8-2.1 mm)[17], LGE images at matching cine-image
slice locations were required 10 to 15 minutes after
cumulative dose of 0.15 mmol/Kg intravenous gadoli-
nium-DTPA administration. The inversion time (250 to
300 ms) was optimized to null the normal myocardium
and adjusted the views per segment and trigger delay
according to the patient’s heart rate.
CMR Image Analysis
All images were reviewed and analyzed off-line with spe-
cialized post-processing software (Cinetool version 3.9.8,
General Electric Healthcare) by two investigators (WSC
and RYK). Analysis and interpretation of all imaging data
were blinded to the clinical data and outcome. The LV
volume measurement, calculation of ejection fraction and
regional wall thickening were analyzed using the same
technique which was reported in the previous study
[18,16]. The LV volumes were determined by planimetry
at the end-systolic and end-diastolic frame, and the LV
myocardial mass was calculated by subtracting the endo-
cardial volume from the epicardial volume at end diastole
and then multiplying by the tissue density (1.05 g/ml).
First-Pass Perfusion Analysis
All first-pass perfusion images were analyzed in short-
axis planes according to the standardized myocardial
segmentation and nomenclature for tomographic
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ment per slice assigned to a coronary artery territory.
For perfusion analysis, the endocardial and epicardial
contours were manually traced and corrected for displa-
cement during breathing. The myocardial signal inten-
sity and arterial input function measured in the basal
L Vs l i c ew e r ed e t e r m i n e df o ra l lt i m ep o i n t s .T h em y o -
cardial blood flow was determined by deconvolution of
myocardial signal intensity curves with an arterial input
function measured in the LV blood pool by using the
Fermi model and expressed in mL/min/gm [20,21]. The
myocardial reserve was calculated from the ratio of
myocardial blood flow during adenosine infusion to
m y o c a r d i a lb l o o df l o wa tr e s ta n du s e da sa ni n d e xf o r
the detection of any changes of myocardial perfusion
after BM injections.
Infarct and Peri-infarct Size Analysis
The endocardial and epicardial contours on delayed
enhancement images were traced manually (Figure 1).
By using a semiautomatic detection algorithm, a signal-
intensity threshold of 2 standard deviations (SDs) above
a reference remote myocardial region on the same slice
was applied to quantify the total infarct mass (MDEtotal)
[10,22,23]. It was further partitioned into the strongly
enhanced core infarct mass (MDEcore)a n dt h ep e r i -
infarct mass (MDEperi-infarct) based on signal-intensity
thresholds of 3 SDs and 2 to 3 SDs above the remote
reference segment, respectively. Infarct size (%MDEtotal)
was expressed as a percentage of LV mass. Furthermore,
normalized MDEperi-infarct and MDEcore as percentages of
the MDEtotal were calculated as previously described
[14].
Statistical Analysis
Data are reported as means ± 1 standard derivation.
Comparisons between paired variables were performed
using Student’s t test, with a significance level of P <
0.05. All statistical analyses were conducted with SPSS
version 13.
Results
The baseline characteristics of the study population are
shown in Table 1. A total of 190 percutaneous catheter-
based endomyocardial injections to 21 ischaemic regions
(inferior = 6, lateral = 5, septal = 5, and anterior = 5) as
guided by the electromechanical mapping were per-
formed in 12 patients without any acute complication.
On average, 16 ± 4 (range 9-23) injections per patient
were performed.
CMR Analysis
There was no significant difference in terms of the hae-
modynamic conditions of patients at 6 months com-
pared with baseline. Compared with baseline, there were
significant improvement in LV ejection fraction (51 ±
Figure 1 (A) The endocardial (LVEN) and epicardial (LVEP) borders at the end diastole of delay enhancement image were trace
manually. The white arrows indicating the extension of transmural myocardial infarction shown up as area of LGE. (B) A computer-assisted
semiautomatic technique was applied to quantify the %MDEperi-infarct. The computer algorithm then used the signal-intensity thresholds of >3
SDs and 2 to 3 SDs above the normal myocardial segment (REMT) to delineate the infarct core (LYMO1- red region) and peri-infarct area (LYMO
2-yellow region) respectively.
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thickening over the targeted regions (48.1 ± 10.2% ver-
sus 53.4 ± 8.6%, P = 0.03)a t6 - m o n t h .H o w e v e r ,t h e r e
were no significant changes in the LV end diastolic
volume (150 ± 33 ml versus 146 ± 30 ml, P = 0.70)a n d
LV mass (99 ± 28 gm/m
2 versus 95.6 ± 28.5 gm/m
2, P
= 0.75) between 6-month and baseline.
Changes in Myocardial Perfusion Reserve
Table 2 shows the values of myocardial blood flow at
rest and during adenosine stress at the targeted and
non-targeted region at baseline and 6 month follow-up.
At baseline, the myocardial perfusion reserve in all
patients was significantly lower at the targeted regions
as compared to non-targeted regions (1.2 ± 0.2 versus
2.1 ± 0.6, P = 0.002), suggestive of significant myocardial
ischaemia at the targeted regions.
As shown in Figure 2, the myocardial perfusion
reserve at the targeted regions after BM cell injection
was significantly increased at 6-month compared with
baseline (1.2 ± 0.3 versus 1.5 ± 0.4, P = 0.03). Neverthe-
less, there was no change in myocardial perfusion
reserve at the non-targeted regions between 6-month
and baseline (2.1 ± 0.6 versus 2.3 ± 0.6, P = 0.20).
Tissue Characterization by LGE
LGE was present in all patients, consistent with prior
myocardial infarction. 75% patients had <50% trans-
mural infarction while the remaining patients had 50-
75% transmural infarction. Compared with baseline,
there was an insignificant modest reduction in the %
MDEtotal at 6-month (-23%, P = 0.06) after BM cell
injection. Nevertheless, there was a significant decrease
in %MDEperi-infarct at 6-month as compared with base-
line (-38%, P = 0.04, Figure 3). However, there was no
significant difference in the transmural extension of
LGE (P = 0.8)
Discussion
The results of this study demonstrate that direct intra-
myocardial implantation of BM cells was associated with
increased myocardial perfusion reserve and regional LV
wall thickening at the targeted ischemic regions. Further-
more, there was a reduction in the extent of ischemic
peri-infarct area detected by CMR, without any signifi-
cant decrease in the extent of core infarct area after BM
cells injection. Taken together, these CMR findings sug-
gest that BM cells implantation improve myocardial per-
fusion reserve and reduce ischaemic peri-infarct region in
human ischemic myocardium, which subsequently contri-
bute to an improvement in regional LV function.
In this study, the mean myocardial perfusion reserve
in the targeted ischaemic regions was significantly lower
Table 1 Baseline characteristics
N=1 2
Age, years 66 ± 9
Men, n (%) 9 (75)
Diabetes mellitus, n (%) 7 (58)
Hyperlipidaemia, n (%) 12
(100)
Hypertension, n (%) 10 (83)
Current cigarette smoker, n (%) 6 (50)
Percutaneous coronary intervention, n (%) 10 (83)
Coronary artery bypass surgery, n (%) 7 (58)
Injected treatment site, n (%):
Inferior wall 7 (32)
Lateral wall 2 (9)
Anterior wall 5 (23)
Septal wall 8 (36)
Medication at baseline, n (%)
Angiotensin-converting enzyme inhibitors or angiotensin-
receptor blockers
6 (50)
Aspirin and/or clopidogrel 16
(100)
b- blockers 12
(100)
Calcium channel blockers 8 (67)
Nitrates 12
(100)
Statins 16
(100)
Medication at 6 months, n (%)
Angiotensin-converting enzyme inhibitors or angiotensin-
receptor blockers
6 (50)
Aspirin and/or clopidogrel 16
(100)
b- blockers 12
(100)
Calcium channel blockers 7 (58)
Nitrates 11 (92)
Statins 16
(100)
Table 2 Myocardial blood flow at rest and during adenosine stress at the targeted and non-targeted region at
baseline and at 6 months after bone marrow cell injection
Baseline 6 month follow-up
Rest
mL/min/gm
Adenosine Stress
mL/min/gm
Rest
mL/min/gm
Adenosine Stress mL/min/gm
Targeted regions 0.67 ± 0.17 0.83 ± 0.16 0.75 ± 0.3 1.12 ± 0.5
Non-targeted regions 0.97 ± 0.9 2.01 ± 0.7 1.01 ± 0.5 2.3 ± 0.7
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geted regions have more tissue ischaemia at baseline.
The improvement in myocardial perfusion reserve was
related to an increase in peak flow rather than a
decrease in baseline flow, suggesting enhancement of
stress induced myocardial blood flow after BM cell
implantation. This postulation is further evidenced by
the reduction in the extent of ischaemic myocardium at
6-month after BM cells implantation compared with
baseline.
Furthermore, the lack of significant reduction in core
infarct area after BM cells implantation indicates the
lack of significant myocardial regeneration over the scar
area. These results are consistent with the findings in
recent experimental studies which showed limited cap-
ability of BM cells to trans-differentiate into cardiomyo-
cytes and continued to differentiate along the
hematopoietic lineage after transplantation [5,6,24].
However, an improvement in LV function was consis-
tently observed in small [5,6] and large animal studies
[7,8,25,26] after BM cells transplantation. Experimental
studies have suggested that the majority of the benefit
effect of BM cells implantation might exert via paracrine
mechanisms with secretion of various angiogenic
Figure 2 Treatment effect of bone marrow (BM) cells implantation on myocardial perfusion reserve in targeted and non-targeted
regions in the BM group as determined by CMR. Data presented as mean ± SD (error bar).
Figure 3 Treatment effect of bone marrow cells (BM) implantation on percentage of total infarct area and peri-infarct area in the BM
group as determined by CMR. Data presented as mean ± SD (error bar).
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induce angiogenesis in myocardial ischemia [8,25,26].
Nevertheless, it remains unclear whether similar para-
crine mechanisms contribute to the improvement in
myocardial perfusion reserve as observed in the present
study.
Study Limitations
First, a small sample size of this study is a limitation as
only patients with detailed CMR examination using the
same protocol and machine were included in this analy-
sis. Therefore, our results need to be confirmed by lar-
ger, prospective, randomized studies. Second, although
t h ec u t o f fo fr e m o t e+ 2S Df o rt h ee n t i r ei n f a r c th a s
been validated in previous studies and currently being
practicing in daily clinical application, future studies are
still needed to validate the used a pre-specified, arbitrary
signal intensity threshold (remote+ 3 SD) above the
remote myocardium to delineate the core infarct on
LGE. Final, whether the treatment effects of BM cells
implantation noted after 6 months are sustained over
time needs to be studied.
Conclusion
In conclusion, our data from CMR provide insights into
the potential functional effects of catheter-based direct
intramyocardial delivery of BM cells in the chronic
human ischemic myocardium.
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